Compare TVGN & DAVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TVGN | DAVI |
|---|---|---|
| Founded | 2020 | 2022 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Blank Checks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.3M | 25.0M |
| IPO Year | 2021 | 2025 |
| Metric | TVGN | DAVI |
|---|---|---|
| Price | $6.10 | $0.93 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 7.8K | ★ 369.2K |
| Earning Date | 11-16-2026 | 04-06-2027 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.14 | $0.91 |
| 52 Week High | $24.91 | $6.05 |
| Indicator | TVGN | DAVI |
|---|---|---|
| Relative Strength Index (RSI) | 48.25 | 14.26 |
| Support Level | $5.01 | $0.91 |
| Resistance Level | $7.22 | $1.18 |
| Average True Range (ATR) | 0.42 | 0.23 |
| MACD | 0.08 | 0.06 |
| Stochastic Oscillator | 53.23 | 7.60 |
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The first clinical product of ExacTcell, TVGN 489, is initially being developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic, lingering symptoms of the disease (Long COVID). Viruses, including COVID-19, hijack cellular machinery to transform infected cells into virus production plants.
Davion Healthcare PLC is focus on developing its range of home tests for a range of home test products, to identify potential medical conditions and provide early warning to enable further clinical examination where applicable. It designs, develops, and patents medical products and non-diagnostic devices and then licenses the manufacturing, marketing, sales, and distribution rights for its products to regional or world-wide commercial partners. The company has been operating as a single segment. Its products are BreastCheck, FootFlow, and Testic.